Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCTX NASDAQ:MTVA OTCMKTS:NVLNF OTCMKTS:OMGAQ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTXBriacell Therap$0.80-4.0%$2.88$0.69▼$29.40$5.41M1.27748,170 shs1.55 million shsMTVAMetaVia$0.67+0.4%$0.70$0.60▼$4.73$13.20M0.2165,546 shs41,395 shsNVLNFNovelion Therapeutics$0.70-1.2%$0.70$0.51▼$1.00$13.77M2.15261,364 shs26,900 shsOMGAQOmega Therapeutics$0.02-63.0%$0.12$0.01▼$1.99$1.23M0.63893,541 shs294,621 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTXBriacell Therap0.00%-60.48%-74.41%-81.39%-94.22%MTVAMetaVia0.00%-6.14%-3.73%-8.81%+67,389,900.00%NVLNFNovelion Therapeutics0.00%0.00%0.00%0.00%0.00%OMGAQOmega Therapeutics0.00%-82.24%-82.24%-82.24%-98.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCTXBriacell Therap1.4556 of 5 stars3.52.00.00.00.60.00.6MTVAMetaViaN/AN/AN/AN/AN/AN/AN/AN/ANVLNFNovelion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOMGAQOmega Therapeutics2.2812 of 5 stars3.40.00.00.01.11.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCTXBriacell Therap 3.00Buy$32.003,908.52% UpsideMTVAMetaVia 3.00Buy$7.501,012.92% UpsideNVLNFNovelion Therapeutics 0.00N/AN/AN/AOMGAQOmega Therapeutics 2.80Moderate Buy$8.5038,188.29% UpsideCurrent Analyst Ratings BreakdownLatest OMGAQ, MTVA, NVLNF, and BCTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025MTVAMetaViaMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $3.004/22/2025BCTXBriacell TherapHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCTXBriacell TherapN/AN/AN/AN/A($2.20) per shareN/AMTVAMetaViaN/AN/AN/AN/A$0.92 per shareN/ANVLNFNovelion Therapeutics$130.43M0.11N/AN/A($4.69) per share-0.15OMGAQOmega Therapeutics$3.09M0.40N/AN/A$1.05 per share0.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCTXBriacell Therap-$4.79M-$8.32N/AN/AN/AN/A-479.97%-182.26%N/AMTVAMetaVia-$27.59MN/A0.00N/AN/AN/A-222.13%-123.85%8/13/2025 (Estimated)NVLNFNovelion Therapeutics-$108.33MN/A0.00∞N/AN/AN/AN/AN/AOMGAQOmega Therapeutics-$97.43M-$1.33N/AN/AN/AN/AN/AN/AN/ALatest OMGAQ, MTVA, NVLNF, and BCTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025MTVAMetaVia-$0.32N/AN/AN/AN/AN/A6/13/2025Q3 2025BCTXBriacell Therap-$1.76-$1.64+$0.12-$1.64N/AN/A5/14/2025Q1 2025MTVAMetaVia-$0.57-$0.36+$0.21-$0.36N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCTXBriacell TherapN/AN/AN/AN/AN/AMTVAMetaViaN/AN/AN/AN/AN/ANVLNFNovelion TherapeuticsN/AN/AN/AN/AN/AOMGAQOmega TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCTXBriacell TherapN/A3.413.41MTVAMetaViaN/A1.551.55NVLNFNovelion TherapeuticsN/AN/AN/AOMGAQOmega TherapeuticsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCTXBriacell Therap15.42%MTVAMetaVia1.37%NVLNFNovelion Therapeutics48.64%OMGAQOmega Therapeutics97.47%Insider OwnershipCompanyInsider OwnershipBCTXBriacell Therap5.73%MTVAMetaVia0.80%NVLNFNovelion Therapeutics3.60%OMGAQOmega Therapeutics8.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCTXBriacell Therap86.78 million6.39 millionNo DataMTVAMetaVia819.59 million19.43 millionN/ANVLNFNovelion Therapeutics10919.62 millionN/ANot OptionableOMGAQOmega Therapeutics12055.37 million50.66 millionOptionableOMGAQ, MTVA, NVLNF, and BCTX HeadlinesRecent News About These CompaniesOmega Therapeutics Inc (OMGAQ)March 5, 2025 | investing.comHuge distressed drugmaker seeks sale in Chapter 11 bankruptcyFebruary 27, 2025 | msn.comIntrommune Therapeutics Announces Publication of OMEGA Study in Peanut Allergic Adults in Annals of Allergy, Asthma & ImmunologyFebruary 19, 2025 | markets.businessinsider.comOmega Therapeutics secures $9.8M in DIP financingFebruary 14, 2025 | msn.comOmega Therapeutics Hits Chapter 11February 10, 2025 | usaherald.comUFlagship’s Omega Thera to file for bankruptcyFebruary 5, 2025 | thepharmaletter.comTFlagship-backed Omega signals it’s headed toward bankruptcyFebruary 5, 2025 | biopharmadive.comBThe OMGA Conundrum: Why Omega Therapeutics Inc’s Stock Is Making Headlines AgainFebruary 5, 2025 | bovnews.comBNovo Partner Omega Waves Bankruptcy Flag from Sinking ShipFebruary 4, 2025 | biospace.comBFlagship spinout Omega is days away from bankruptcy, it says in filingFebruary 4, 2025 | endpts.comEWhat’s Behind the 11.36% Gain in Omega Therapeutics Inc (OMGA) Stock? Find Out Now!January 30, 2025 | bovnews.comBOmega Therapeutics announces board reshuffle and new directorJanuary 29, 2025 | msn.comFlagship Pioneering partners with Cambridge, UK institutionsJanuary 25, 2025 | thepharmaletter.comTOmega Therapeutics stock hits 52-week low at $0.52January 21, 2025 | msn.comOmega Therapeutics Appoints New Director Ravi MehrotraDecember 6, 2024 | tipranks.comOmega Pacific Reports Its Final Drill Hole Yielding Multiple Zones of Mineralization at Its Williams PropertyDecember 4, 2024 | accesswire.comAOmega Pacific Announces 2024 Work Program Results From Its Lekcin PropertyNovember 19, 2024 | accesswire.comAOmega Therapeutics Reports Third Quarter 2024 ResultsNovember 19, 2024 | markets.businessinsider.comOmega Therapeutics price target lowered to $4 from $9 at Piper SandlerNovember 16, 2024 | markets.businessinsider.comPiper Sandler Remains a Buy on Omega Therapeutics (OMGA)November 16, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOMGAQ, MTVA, NVLNF, and BCTX Company DescriptionsBriacell Therap NASDAQ:BCTX$0.80 -0.03 (-3.98%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.81 +0.02 (+1.97%) As of 07/18/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.MetaVia NASDAQ:MTVA$0.67 +0.00 (+0.43%) As of 07/18/2025 04:00 PM EasternMetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.Novelion Therapeutics OTCMKTS:NVLNF$0.70 -0.01 (-1.20%) As of 01/16/2020Novelion Therapeutics Inc., a biopharmaceutical company, develops therapies for individuals living with rare diseases in the United States, Japan, Brazil, and internationally. Its commercial products include metreleptin, a recombinant analog of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPTA brand name; and lomitapide capsule for the treatment of adult patients with homozygous familial hypercholesterolemia under the JUXTAPID and LOJUXTA brands. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.Omega Therapeutics OTCMKTS:OMGAQ$0.02 -0.04 (-63.00%) As of 07/18/2025 03:59 PM EasternOmega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
